Paragraf secures €46.9M Series C to scale graphene chip production

Share now

Read this article in:

Paragraf secures €46.9M Series C to scale graphene chip production
© Paragraf

Paragraf, a UK-based developer of graphene-based electronic devices, has raised $55 million (~€46.9 million) in a Series C round to expand manufacturing capacity and bring its technology into mass-market applications.

Founded in 2015, Paragraf produces magnetic sensors and Graphene Molecular Sensors (GMS) using standard semiconductor processes. Its proprietary graphene growth technology enables chips that operate faster, with greater precision, and lower energy use compared to silicon — even in extreme environments such as cryogenic, high-temperature, or high-radiation conditions.

Applications across industries

Paragraf’s GMS technology underpins liquid and gas sensors for early disease detection and has broader use cases in healthcare, agritech, food and chemical manufacturing, and consumer products. The company positions its platform as compatible with the existing semiconductor ecosystem, enabling tailored applications for customers.

Currently, Paragraf operates three facilities: two in Cambridgeshire, UK, and one in San Diego, US (via a 2023 acquisition). It has an active presence across the US, Europe, the Middle East, and Asia.

Advertisement

Scaling global production

The new capital will be used to expand manufacturing capacity, increase production output, and accelerate commercialization across global markets.

“This investment is a strong signal of confidence in Paragraf and our mission in the face of global economic uncertainty,” said Dr. Simon Thomas, co-founder and CEO. “We can now expand production of faster, more energy-efficient technologies to the scale required by major commercial opportunities.”

Backed by deep tech investors

The round attracted support from both new and existing backers, including Amadeus Capital Partners, British Patient Capital, Cambridge University, IQ Capital, Molten, Mubadala Capital, New Science Ventures, and Parkwalk Advisors.

Advertisement

Get the top Stories in your Inbox

Sign up for our Newsletters
[mc4wp_form id="399"]

Specials from our Partners

Previous
Next